The Role of Biosimilars in Managing Inflammatory Disease
Mon Feb 02 2026
With the number of biosimilar products steadily increasing, pharmacists play a central role in ensuring their appropriate use in inflammatory conditions. This episode highlights approval pathways, interchangeability, and real-world challenges pharmacists may face when integrating biosimilars into care plans. You will walk away better prepared to support prescribers, counsel patients, and contribute to cost-effective, evidence-informed therapy decisions.
HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Clinical Editor, CEimpact
Lead Editor, Pyrls
GUEST
Reemal Zaheer, PharmD, CSP
Pharmacist
Johns Hopkins Medicine
GAMECHANGERS CLINICAL UPDATE SERIES
The Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll.
PRACTICE RESOURCE
Purchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast.
CPE REDEMPTION
This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:
If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here.
CPE INFORMATION
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Explain the role of biosimilars in the treatment of inflammatory conditions.
2. Describe considerations for the pharmacist when evaluating or counseling on biosimilar therapies.
Rachel Maynard and Reemal Zaheer have no relevant financial relationships with ineligible companies to disclose.
0.075 CEU/0.75 Hr
UAN: 0107-0000-26-045-H01-P
Initial release date: 2/2/2026
Expiration date: 2/2/2027
Additional CPE details can be found here.
Follow CEimpact on Social Media:
LinkedIn
Instagram
More
With the number of biosimilar products steadily increasing, pharmacists play a central role in ensuring their appropriate use in inflammatory conditions. This episode highlights approval pathways, interchangeability, and real-world challenges pharmacists may face when integrating biosimilars into care plans. You will walk away better prepared to support prescribers, counsel patients, and contribute to cost-effective, evidence-informed therapy decisions. HOST Rachel Maynard, PharmD GameChangers Podcast Host and Clinical Editor, CEimpact Lead Editor, Pyrls GUEST Reemal Zaheer, PharmD, CSP Pharmacist Johns Hopkins Medicine GAMECHANGERS CLINICAL UPDATE SERIES The Clinical Update Series for Pharmacists delivers 52 expert-led podcast episodes and 30+ hours of clinically actionable continuing education, all for a one-time purchase of just $99—that’s less than $3 per hour for high-impact learning you can apply immediately in practice. Click here to enroll. PRACTICE RESOURCE Purchase the Clinical Update Series or this course individually to receive the exclusive downloadable practice resource handout to use as a reference guide to the podcast. CPE REDEMPTION This course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation: If you are already enrolled in this course, click here to redeem your credit. To purchase the Clinical Update Series and claim your CPE credit, click here or to purchase this course individually, click here. CPE INFORMATION Learning Objectives Upon successful completion of this knowledge-based activity, participants should be able to: 1. Explain the role of biosimilars in the treatment of inflammatory conditions. 2. Describe considerations for the pharmacist when evaluating or counseling on biosimilar therapies. Rachel Maynard and Reemal Zaheer have no relevant financial relationships with ineligible companies to disclose. 0.075 CEU/0.75 Hr UAN: 0107-0000-26-045-H01-P Initial release date: 2/2/2026 Expiration date: 2/2/2027 Additional CPE details can be found here. Follow CEimpact on Social Media: LinkedIn Instagram